NCT05689671 2026-03-10
ANTELOPE
Charite University, Berlin, Germany
Phase 4 Active not recruiting
Clinical Trials
14 trialsNCT03656549 2024-12-17
IMPROVE-I
Radboud University Medical Center
Phase 4 Completed
NCT06357598 2024-04-10
PILOT
The Affiliated Hospital of Qingdao University
Phase 4 Recruiting
NCT03655821 2022-05-13
IMPROVE-II
Radboud University Medical Center
Phase 4 Terminated
NCT03655834 2022-05-10
IMPROVE-III
Radboud University Medical Center
Phase 4 Completed
NCT03607149 2021-05-24
PKAPIR
Centre Georges Francois Leclerc
Phase 4 Completed
NCT03460678 2020-03-05
Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
Hikma Pharmaceuticals LLC
Phase 4 Terminated
NCT01665417 2017-02-08
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT02804646 2016-06-21
Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Anhui Provincial Hospital
Phase 4 Unknown
NCT02031601 2016-03-29
TCL-1
Qilu Hospital of Shandong University
Phase 4 Unknown
NCT02103257 2015-04-29
Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT02399566 2015-03-26
Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
Hunan Province Tumor Hospital
Phase 4 Unknown
NCT01442909 2011-09-29
Pemetrexed Followed by Docetaxel or in Reverse Sequence
Taipei Veterans General Hospital, Taiwan
Phase 4 Completed
NCT00380718 2010-11-16
Chemotherapy for Patients With Non-Small Cell Lung Cancer
Eli Lilly and Company
Phase 4 Completed